Log In
Print
BCIQ
Print
Print this Print this
 

Relonsiv (NU100) (formerly BaroFeron)

  Manage Alerts
Collapse Summary General Information
Company BaroFold Inc.
DescriptionRecombinant interferon (IFN) beta-1b
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase III
Standard IndicationMultiple sclerosis (MS)
Indication DetailsTreat multiple sclerosis (MS); Treat relapsing-remitting multiple sclerosis (RRMS)
Regulatory Designation

Partner

Avecia Ltd.; Nuron Biotech Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today